Last year was a record launch year for Medis with 123 launches within the year. The majority of launches were within Europe, Germany and France being our key launch markets. However, the emerging markets are now playing a significantly larger role in total launch volume and value than in previous years.
For 2012, the landscape appears similar in terms of total launches with an estimated 120 launches. The key markets will be within Europe but the launch value for the emerging markets will continue to increase.
Medis’ next significant launch is for one of the world’s largest molecule, Atorvastatin Calcium. The launch is planned in May 2012 for most of Western Europe at the day of patent expiry.